CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843199512
- Phone
- (214) 612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-10 | Nagendran Sukumar President and Head of R&D | Sale 10b5-1 | −200,000 | $6.24 | $1.2M | 936,410 |
| 2026-06-01 | Long Alison S Director | Grant or award | +21,335 | 127,178 | ||
| 2026-06-01 | Long Alison S Director | Grant or award · Stock Option (right to buy) | +42,671 | 42,671 | ||
| 2026-06-01 | Sepp-Lorenzino Laura Director | Grant or award | +21,335 | 127,178 | ||
| 2026-06-01 | Sepp-Lorenzino Laura Director | Grant or award · Stock Option (right to buy) | +42,671 | 42,671 | ||
| 2026-06-01 | Stalfort John A III Director | Grant or award | +21,335 | 1,176,559 | ||
| 2026-06-01 | Stalfort John A III Director | Grant or award · Stock Option (right to buy) | +42,671 | 42,671 | ||
| 2026-06-01 | Donenberg Phillip B. Director | Grant or award | +21,335 | 241,289 | ||
| 2026-06-01 | Donenberg Phillip B. Director | Grant or award · Stock Option (right to buy) | +42,671 | 42,671 | ||
| 2026-04-10 | Nagendran Sukumar President and Head of R&D | Option exercise 10b5-1 | +19,021 | $1.71 | $33K | 1,336,410 |
| 2026-04-10 | Nagendran Sukumar President and Head of R&D | Sale 10b5-1 | −200,000 | $4.46 | $892K | 1,136,410 |
| 2026-04-10 | Nagendran Sukumar President and Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −19,021 | 455,920 | ||
| 2026-02-04 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | −1,655 | $4.52 | $7K | 1,442,131 |
| 2026-01-26 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | −23,849 | $4.61 | $110K | 1,443,786 |
| 2026-01-26 | Nagendran Sukumar President and Head of R&D | Sale | −26,918 | $4.61 | $124K | 1,317,389 |
| 2026-01-26 | Nolan Sean P. Chief Executive Officer | Sale | −41,312 | $4.61 | $190K | 2,908,257 |
| 2026-01-23 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | −78,968 | $4.75 | $375K | 1,467,635 |
| 2026-01-23 | Nagendran Sukumar President and Head of R&D | Sale | −89,132 | $4.75 | $423K | 1,344,307 |
| 2026-01-23 | Nolan Sean P. Chief Executive Officer | Sale | −136,789 | $4.75 | $650K | 2,949,569 |
| 2026-01-12 | Alam Kamran CHIEF FINANCIAL OFFICER | Grant or award | +359,000 | 1,546,603 |
Page 1 of 9 · 173 trades